×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| Shyama Computronics and Servic | 0.70 | 0.19 | 0.61 | NA | 4.02 | 30.9 |
| Triochem Products Ltd., | 4.59 | 0.88 | NA | 3.60 | 0 | |
| Dishman Carbogen Amcis Limited | 6879.7 | 46.3 | 6823.4 | 0.30 | 3,454 | |
| Advanced Enzyme Technologies L | 1,767.97 | 388.76 | 1,691.12 | 3.36 | 3244 | 22.8 |
| MOREPEN LABORATORIES LTD. | 4581.18 | 266.89 | 4527.81 | 0.49 | 2837 | 22.5 |
Dishman Carbogen Amcis Limited, with Security Code 540701, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 103.6 | 106.5 | 78.4 | 113.1 | 69.5 | 59.7 | 86.8 | 111.2 | 103.4 | 93.2 |
| Expenses | 101.1 | 105.4 | 81.6 | 106.8 | 74.6 | 62.6 | 83.7 | 99.7 | 88.5 | 79.9 |
| Operating Profit | 2.6 | 1.2 | -3.2 | 6.4 | -5.0 | -2.9 | 3.2 | 11.6 | 14.9 | 13.4 |
| OPM % | 2.47% | 1.08% | -4.08% | 5.61% | -7.22% | -4.89% | 3.65% | 10.4% | 14.41% | 14.36% |
| Other Income | 5.0 | 20.9 | 10.4 | 14.8 | 14.4 | 35.7 | 13.1 | -3.2 | 11.6 | 23.9 |
| Interest | 12.6 | 13.6 | 14.7 | 17.0 | 17.8 | 17.4 | 17.1 | 15.9 | 15.7 | 15.6 |
| Depreciation | 34.7 | 35.2 | 2.9 | 23.5 | 24.7 | 24.6 | 26.2 | 26.1 | 16.3 | 16.3 |
| Profit before tax | -39.7 | -26.8 | -8.4 | -19.3 | -33.0 | -6.2 | -27.1 | -33.6 | -5.6 | 5.4 |
| Tax % | -37.4% | -35.5% | -37.1% | -47.1% | -35.4% | -37.6% | -32.9% | -7.5% | -37.6% | 161.9% |
| Net Profit | -24.8 | -17.3 | -6.5 | -10.2 | -21.3 | -5.8 | -18.2 | -31.1 | -3.5 | 14.3 |
| EPS in Rs | -1.58 | -1.1 | -0.42 | -0.65 | -1.36 | -0.37 | -1.16 | -1.98 | -0.22 | 0.91 |
| Metrics | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 614.0 | 639.8 | 618.6 | 723.4 | 586.6 | 651.1 | 654.7 | 523.8 | 789.0 | 682.3 |
| Expenses | 535.4 | 525.9 | 567.1 | 601.5 | 525.7 | 610.0 | 592.0 | 494.8 | 641.9 | 542.2 |
| Operating Profit | 78.6 | 113.9 | 51.4 | 121.9 | 60.9 | 41.1 | 62.7 | 29.0 | 147.2 | 140.1 |
| OPM % | 12.8% | 17.8% | 8.3% | 16.8% | 10.4% | 6.3% | 9.6% | 5.5% | 18.6% | 20.5% |
| Other Income | 8.9 | 4.0 | -38.9 | 6.5 | 5.4 | 6.1 | 4.1 | -4.0 | 3.7 | 7.7 |
| Interest | 20.2 | 21.9 | 24.4 | 28.5 | 27.5 | 33.1 | 31.0 | 31.9 | 36.6 | 48.8 |
| Depreciation | 79.6 | 50.3 | 75.7 | 70.5 | 75.0 | 80.4 | 85.0 | 70.6 | 72.1 | 72.0 |
| Profit before tax | -12.3 | 48.1 | -42.0 | 29.5 | -33.2 | -66.3 | -46.1 | -72.1 | 45.1 | 25.0 |
| Tax % | -18.2% | 3% | -19.3% | 42.4% | -12.8% | -10% | -42.1% | -0% | 21.4% | 82.9% |
| Net Profit | -10.1 | 47.0 | -70.7 | 17.0 | -40.9 | -59.6 | -69.9 | -77.6 | 33.1 | 4.6 |
| EPS in Rs | 0 | 3 | -4 | 1 | -2 | -3 | -4 | -4 | 2 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -10% |
| 3 Years: | 18% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 19% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 19% |
| 3 Years: | 9% |
| 1 Year: | -8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 5% |
| 3 Years: | 11% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 4% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 19% |
| 3 Years: | 9% |
| 1 Year: | -8% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|